EGFR is a potential dual molecular target for cancer and Alzheimer's disease

Area of Science:

• Neuroscience
• Oncology
• Pharmacology

Background:

• Alzheimer's disease (AD) lacks effective treatments, prompting research into drug repurposing.
• Epidermal growth factor receptor (EGFR) inhibitors, established anti-cancer drugs, are emerging as potential AD therapeutics.
• EGFR plays roles in both cancer and neurodegenerative processes relevant to AD.

Purpose of the Study:

• To review the dual functions of EGFR in cancer and Alzheimer's disease.
• To evaluate the potential of EGFR as a molecular target for AD therapy.
• To discuss the therapeutic prospects of anti-cancer EGFR tyrosine kinase inhibitors (TKIs) for AD.

Main Methods:

• Literature review of studies on EGFR function in cancer and AD.
• Analysis of research on EGFR inhibitors in AD mouse models.
• Synthesis of findings on the effects of EGFR TKIs on AD pathology and cognition.

Main Results:

• EGFR inhibitors approved for cancer treatment demonstrate potential for AD therapy.
• Studies in AD mouse models indicate EGFR inhibitors can reduce amyloid-beta pathology.
• EGFR inhibitors have shown to improve cognitive function in AD models.

Conclusions:

• EGFR is a significant molecular target for both cancer and Alzheimer's disease.
• EGFR tyrosine kinase inhibitors (TKIs) represent a promising therapeutic strategy for AD.
• Repurposing anti-cancer EGFR inhibitors offers a viable avenue for novel AD treatments.